戻る Agenda
Where is the Orphan Drug Journey Going?
Session Chair(s)
Mark Rutter
Co-Founder, Head of Product Development & Strategy
RxTROSPECT, United States
This session looks at the success of EC Regulation on orphan medicinal products in bringing innovative new therapies to patients with high unmet medical need. We will explore the upcoming changes in the EU orphan environment and what must be maintained and built upon to further stimulate research in this key research area. Session in development
Speaker(s)
Optimisation of the Regulatory Framework for Orphan Medicines to Encourage Innovative Treatments for Patients
Agnes Mathieu-Mendes, RPH
European Health & Digital Executive Agency (HaDEA), Belgium
Head of Unit
Orphan Medicinal Products and the Major Contribution to Patient Care
Jordi Llinares Garcia, MS
European Medicines Agency, Netherlands
Head of Research and Innovation
The Patient’s Perspectives on OMPs and Significant Benefit
Virginie Hivert, PHARMD, PHD
Eurordis-Rare Diseases Europe, France
Therapeutic Development Director
Evolution of the Significant Benefit Framework - An Industry Perspective
Mark Rutter
RxTROSPECT, United States
Co-Founder, Head of Product Development & Strategy